Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058365 | 0.85 | — | — | |
| SCHEMBL14795158 | 0.79 | TP53 (0.38) | — | |
| Hydrochloric Acid SCHEMBL928605 | 0.77 | TP53 (0.36) | — | |
| SCHEMBL28932722 | 0.74 | CA2 (0.37) | CA1CA2 | |
| SCHEMBL16268315 | 0.74 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL1646289 | 0.74 | PSEN1 (0.42) | CA1CA2 | |
| SCHEMBL8085819 | 0.74 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL4189191 | 0.74 | DPP4 (0.41) | — | |
| SCHEMBL8075520 | 0.74 | DPP4 (0.41) | — | |
| SCHEMBL4183223 | 0.74 | CA1 (0.33) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890939-B2 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-6890939-B2 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-6710061-B2 | SELECTIVE SERINE PROTEASE OR DUAL-SERINE PROTEASE INHIBITORS OF FACTOR XA AND TRYPTASE | ORTHO-MCNEIL PHARAMCEUTICAL, INC. | 2004-03-23 | — | — | US | disclosed |
| US-6710061-B2 | SELECTIVE SERINE PROTEASE OR DUAL-SERINE PROTEASE INHIBITORS OF FACTOR XA AND TRYPTASE | ORTHO-MCNEIL PHARAMCEUTICAL, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1385822-A1 | AMINOPYRROLIDINE SULFONAMIDES AS SERINE PROTEASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030203936-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | GRECO MICHAEL N (US) | 2003-10-30 | — | — | US | disclosed |
| US-20030203936-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | GRECO MICHAEL N (US) | 2003-10-30 | — | — | US | disclosed |
| US-6630505-B2 | Inhibitors of Factor Xa and tryptase useful for treating serine protease or dual-serine protease mediated disorders such as thrombotic disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6630505-B2 | Inhibitors of Factor Xa and tryptase useful for treating serine protease or dual-serine protease mediated disorders such as thrombotic disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030166681-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030166681-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030166680-A1 | AMINOPYRROLIDINE SULFONAMIDES AS SERINE PROTEASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6538017-B2 | Anticoagulants; cardiovascular disorders; central nervous system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-25 | — | — | US | disclosed |
| US-6538017-B2 | Anticoagulants; cardiovascular disorders; central nervous system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-25 | — | — | US | disclosed |
| US-20030004186-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2003-01-02 | — | — | US | disclosed |
| US-20030004186-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002076945-A1 | AMINOPYRROLIDINE SULFONAMIDES AS SERINE PROTEASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166681-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | PRSS1, DNPEP, PRSS2 | CA1 1668/4885CA2 1324/4885 |
| US-20030203936-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | PRSS1, DNPEP, PRSS2 | CA1 1668/4885CA2 1324/4885 |
| US-20030004186-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | PRSS1, DNPEP, PRSS2 | CA1 1668/4885CA2 1324/4885 |
| US-20030166680-A1 | AMINOPYRROLIDINE SULFONAMIDES AS SERINE PROTEASE INHIBITORS | PRSS1, DNPEP, PRSS2 | CA1 1668/4885CA2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.